Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 4

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 4
---
 outstanding shall
remain unchanged. Any reduction to the exercise price of the Series L Warrants and resulting increase in the Depositary Shares underlying
the Series L Warrants will be subject to a floor price. The floor price will be equal to 30% of the Latest NASDAQ Closing Price. For the
avoidance of doubt, the lower that the stock price of our Depositary Shares is on the First Reset Date and Second Reset Date, as applicable,
the more shares that will be issuable pursuant to the Series L Warrants as a result of the each reset, subject to the floor price of 50%
of the Latest NASDAQ Closing Price on the First Reset Date, and 30% of the Latest NASDAQ Closing Price on the Second Reset Date.

Please see the section of
this prospectus entitled “Description of the Securities we are Offering” for further information.

We are also offering the opportunity to
purchase, if the purchaser so chooses in lieu of Units, up to 3,377,110 pre-funded units, or the Pre-Funded Units, to purchasers whose
purchase of Units in this offering would otherwise result in the purchaser, together with its affiliates, beneficially owning more than
4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Ordinary Shares immediately following the consummation of this
offering. Each Pre-Funded Unit consists of (i) one pre-funded warrant exercisable for one Depositary Share, or a Pre-Funded Warrant, and
(ii) one Series L Warrant. Subject to limited exceptions, a holder of Pre-Funded Warrants will not have the right to exercise any portion
of its Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election
of the holder, up to 9.99%) of the number of Ordinary Shares outstanding immediately after giving effect to such exercise. The purchase
price of each Pre-Funded Unit will be equal to the price per Unit being sold to the public in this offering, minus $0.0001, and the exercise
price of each Pre-Funded Warrant included in the Pre-Funded Unit will be $0.0001 per Depositary Share. The Pre-Funded Warrants will be
immediately exercisable (subject to the beneficial ownership cap) and may be exercised at any time until all of the Pre-Funded Warrants
are exercised in full.